Celecoxib Treatment for Lung Cancer

US Department of Veterans Affairs (VA)

Status and phase: Withdrawn; Phase 1

Conditions: Non-Small-Cell Lung Carcinoma

Treatments: Drug: Celecoxib

Study type: Interventional

Funder types: Other; Other U.S. Federal agency

Identifiers

NCT00108186

ONCA-043-04S

Details and patient eligibility

About

This proposal evaluates cyclooxygenase 2 (COX-2) inhibition as a means to decrease T regulatory cell activities and thus augment immune responses against lung cancer. The broad goal focuses on understanding how COX-2 expression regulates the malignant phenotype in non small cell lung cancer in an effort to foster an informed approach for the use of COX-2 inhibitors in prevention and therapy for lung cancer.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pathologically confirmed and surgically resectable non small cell lung cancer and subjects must be ineligible for or refuse, neoadjuvant therapy

Exclusion criteria

Hypersensitivity to celecoxib or NSAIDs, previous history of GI bleeding or ulceration, chronic or concurrent use of steroids and renal insufficiency

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Arm 1

Other group

Description:

Celecoxib is an FDA approved drug for other indications such as osteoarthritis. It is not FDA approved for non-small cell lung cancer.

Treatment:

Drug: Celecoxib